title: Acute ventricular reduction with the acorn cardiac support device: effect on progressive left ventricular dysfunction and dilation in dogs with chronic heart failure.
abstract: OBJECTIVE
  Surgical resection of myocardium that acutely reduces left ventricular (LV) volume in patients with advanced heart failure (HF), the so-called "Batista Operation," remains controversial. We examined the effects of acute LV reduction with the Acorn Cardiac Support Device (CSD) in dogs with HF (LV ejection fraction < 30%).
  
  
  METHODS
  HF was produced in 15 dogs by intracoronary microembolization. In nine dogs, intravenous dobutamine was administered to reduce LV end-diastolic dimension (LVEDD) by 10%-25%. While on dobutamine infusion, the CSD, a preformed knitted polyester device, was surgically placed around the ventricles, anchored to the arteriovenous (AV) groove, and tailored anteriorly to fit snugly over the ventricles. Dogs were then weaned off dobutamine.
  
  
  RESULTS
  On average, the procedure reduced LVEDD by 7 +/- 1 mm (range 5-12 mm). Of the nine dogs, two died before completion of the study and seven survived for the entire period. Six dogs did not undergo device placement and served as controls. All were followed for 3 months prior to sacrifice. In controls, LV end-diastolic volume increased after 3 months (66 +/- 5 mL vs 77 +/- 6 mL; p = 0.007), while in CSD-treated dogs (n = 7), it decreased (80 +/- 5 mL vs 60 +/- 3 mL; p = 0.002). In controls, LV ejection fraction (EF) decreased after 3 months (27 +/- 1% vs 23 +/- 1%; p = 0.001) but was unchanged in CSD-treated dogs (25 +/- 1% vs 26 +/- 1%; p = 0.66). Compared to controls, CSD-treated dogs showed improved LV diastolic dysfunction and chamber sphericity, decreased wall stress, and no functional mitral regurgitation (MR).
  
  
  CONCLUSIONS
  In dogs with advanced HF, acute LV reduction with the Acorn CSD prevents progressive global LV dilatation and ameliorates functional MR.
authors.affiliation: Department of Medicine, Henry Ford Heart and Vascular Institute Henry Ford Health System, Detroit, Michigan, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: Chaudhry
authors.forename: P V
authors.initials: PV
authors.lastname: Anagnostopouls
authors.forename: T
authors.initials: T
authors.lastname: Mishima
authors.forename: G
authors.initials: G
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Nair
authors.forename: H
authors.initials: H
authors.lastname: Morita
authors.forename: V G
authors.initials: VG
authors.lastname: Sharov
authors.forename: C
authors.initials: C
authors.lastname: Alferness
authors.forename: H N
authors.initials: HN
authors.lastname: Sabbah
mesh_terms: D000208:Acute Disease; D000818:Animals; D002908:Chronic Disease; D017023:Coronary Angiography; D004108:Dilatation, Pathologic / Q000517:prevention & control; D018450:Disease Progression; D004285:Dogs; D015150:Echocardiography, Doppler; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D006353:Heart-Assist Devices; D012720:Severity of Illness Index; D013318:Stroke Volume; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000517:prevention & control*; D020257:Ventricular Remodeling